AMI 569
Alternative Names: AMI-569Latest Information Update: 11 Sep 2024
At a glance
- Originator Avirmax Biopharma
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Dry macular degeneration
Most Recent Events
- 01 Aug 2024 Preclinical trials in Dry macular degeneration in USA (Intravitreous), prior to August 2023 (Avirmax Biopharma pipeline; August 2024)
- 01 Aug 2024 Avirmax Biopharma announces intention to submit IND application to regulatory body for Dry macular degeneration in second half of 2024 (Avirmax Biopharma pipeline, August 2024)